Clinical research in primary stroke prevention

Needs, opportunities, and challenges

Barbara Radziszewska, Robert G. Hart, Philip A. Wolf, Ralph B. D'Agostino, Jeffrey A. Cutler, Joseph P. Broderick, Bruce M Coull, Mary Cushman, Ralph B. D'Agostino, Donald J. Easton, Paula Einhorn, Larry B. Goldstein, Philip B. Gorelick, Steven Haffner, George Howard, S. Claiborne Johnston, Walter Kernan, Will Longstreth, Dilip K. Pandey, Joseph F. Polak & 4 others Ralph L. Sacco, Daniel E. Singer, James Toole, Steven J. Warach

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Most (∼70%) of strokes are first-ever strokes, and hence to substantially reduce the neurological burden, primary prevention is crucial. Here, highlights of the National Institute of Neurological Disorders and Stroke workshop 'Stroke Risk Assessment and Future Stroke Primary Prevention Trials' held January 12-13, 2004 are summarized. The Workshop discussions focused on stroke risk assessment; the high-risk vs. population-based approaches to primary prevention; desirable characteristics of candidate treatments and potential novel treatments, such as the 'polypill'; subclinical disease as risk assessment tool and as surrogate outcome, and methodological issues in stroke primary prevention trials. The importance of assessing cognitive decline as an important consequence of covert and overt vascular injury of the brain was emphasized. The scientific or logistic barriers to stroke primary prevention trials are challenging, but are not insurmountable.

Original languageEnglish (US)
Pages (from-to)91-104
Number of pages14
JournalNeuroepidemiology
Volume25
Issue number2
DOIs
StatePublished - 2005

Fingerprint

Primary Prevention
Stroke
Research
Cerebrovascular Trauma
National Institute of Neurological Disorders and Stroke
Education
Population

Keywords

  • Clinical trial
  • Primary prevention
  • Risk factors
  • Stroke prevention

ASJC Scopus subject areas

  • Epidemiology
  • Clinical Neurology

Cite this

Radziszewska, B., Hart, R. G., Wolf, P. A., D'Agostino, R. B., Cutler, J. A., Broderick, J. P., ... Warach, S. J. (2005). Clinical research in primary stroke prevention: Needs, opportunities, and challenges. Neuroepidemiology, 25(2), 91-104. https://doi.org/10.1159/000086342

Clinical research in primary stroke prevention : Needs, opportunities, and challenges. / Radziszewska, Barbara; Hart, Robert G.; Wolf, Philip A.; D'Agostino, Ralph B.; Cutler, Jeffrey A.; Broderick, Joseph P.; Coull, Bruce M; Cushman, Mary; D'Agostino, Ralph B.; Easton, Donald J.; Einhorn, Paula; Goldstein, Larry B.; Gorelick, Philip B.; Haffner, Steven; Howard, George; Johnston, S. Claiborne; Kernan, Walter; Longstreth, Will; Pandey, Dilip K.; Polak, Joseph F.; Sacco, Ralph L.; Singer, Daniel E.; Toole, James; Warach, Steven J.

In: Neuroepidemiology, Vol. 25, No. 2, 2005, p. 91-104.

Research output: Contribution to journalArticle

Radziszewska, B, Hart, RG, Wolf, PA, D'Agostino, RB, Cutler, JA, Broderick, JP, Coull, BM, Cushman, M, D'Agostino, RB, Easton, DJ, Einhorn, P, Goldstein, LB, Gorelick, PB, Haffner, S, Howard, G, Johnston, SC, Kernan, W, Longstreth, W, Pandey, DK, Polak, JF, Sacco, RL, Singer, DE, Toole, J & Warach, SJ 2005, 'Clinical research in primary stroke prevention: Needs, opportunities, and challenges', Neuroepidemiology, vol. 25, no. 2, pp. 91-104. https://doi.org/10.1159/000086342
Radziszewska B, Hart RG, Wolf PA, D'Agostino RB, Cutler JA, Broderick JP et al. Clinical research in primary stroke prevention: Needs, opportunities, and challenges. Neuroepidemiology. 2005;25(2):91-104. https://doi.org/10.1159/000086342
Radziszewska, Barbara ; Hart, Robert G. ; Wolf, Philip A. ; D'Agostino, Ralph B. ; Cutler, Jeffrey A. ; Broderick, Joseph P. ; Coull, Bruce M ; Cushman, Mary ; D'Agostino, Ralph B. ; Easton, Donald J. ; Einhorn, Paula ; Goldstein, Larry B. ; Gorelick, Philip B. ; Haffner, Steven ; Howard, George ; Johnston, S. Claiborne ; Kernan, Walter ; Longstreth, Will ; Pandey, Dilip K. ; Polak, Joseph F. ; Sacco, Ralph L. ; Singer, Daniel E. ; Toole, James ; Warach, Steven J. / Clinical research in primary stroke prevention : Needs, opportunities, and challenges. In: Neuroepidemiology. 2005 ; Vol. 25, No. 2. pp. 91-104.
@article{4899683273314e29a78933ca10009522,
title = "Clinical research in primary stroke prevention: Needs, opportunities, and challenges",
abstract = "Most (∼70{\%}) of strokes are first-ever strokes, and hence to substantially reduce the neurological burden, primary prevention is crucial. Here, highlights of the National Institute of Neurological Disorders and Stroke workshop 'Stroke Risk Assessment and Future Stroke Primary Prevention Trials' held January 12-13, 2004 are summarized. The Workshop discussions focused on stroke risk assessment; the high-risk vs. population-based approaches to primary prevention; desirable characteristics of candidate treatments and potential novel treatments, such as the 'polypill'; subclinical disease as risk assessment tool and as surrogate outcome, and methodological issues in stroke primary prevention trials. The importance of assessing cognitive decline as an important consequence of covert and overt vascular injury of the brain was emphasized. The scientific or logistic barriers to stroke primary prevention trials are challenging, but are not insurmountable.",
keywords = "Clinical trial, Primary prevention, Risk factors, Stroke prevention",
author = "Barbara Radziszewska and Hart, {Robert G.} and Wolf, {Philip A.} and D'Agostino, {Ralph B.} and Cutler, {Jeffrey A.} and Broderick, {Joseph P.} and Coull, {Bruce M} and Mary Cushman and D'Agostino, {Ralph B.} and Easton, {Donald J.} and Paula Einhorn and Goldstein, {Larry B.} and Gorelick, {Philip B.} and Steven Haffner and George Howard and Johnston, {S. Claiborne} and Walter Kernan and Will Longstreth and Pandey, {Dilip K.} and Polak, {Joseph F.} and Sacco, {Ralph L.} and Singer, {Daniel E.} and James Toole and Warach, {Steven J.}",
year = "2005",
doi = "10.1159/000086342",
language = "English (US)",
volume = "25",
pages = "91--104",
journal = "Neuroepidemiology",
issn = "0251-5350",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Clinical research in primary stroke prevention

T2 - Needs, opportunities, and challenges

AU - Radziszewska, Barbara

AU - Hart, Robert G.

AU - Wolf, Philip A.

AU - D'Agostino, Ralph B.

AU - Cutler, Jeffrey A.

AU - Broderick, Joseph P.

AU - Coull, Bruce M

AU - Cushman, Mary

AU - D'Agostino, Ralph B.

AU - Easton, Donald J.

AU - Einhorn, Paula

AU - Goldstein, Larry B.

AU - Gorelick, Philip B.

AU - Haffner, Steven

AU - Howard, George

AU - Johnston, S. Claiborne

AU - Kernan, Walter

AU - Longstreth, Will

AU - Pandey, Dilip K.

AU - Polak, Joseph F.

AU - Sacco, Ralph L.

AU - Singer, Daniel E.

AU - Toole, James

AU - Warach, Steven J.

PY - 2005

Y1 - 2005

N2 - Most (∼70%) of strokes are first-ever strokes, and hence to substantially reduce the neurological burden, primary prevention is crucial. Here, highlights of the National Institute of Neurological Disorders and Stroke workshop 'Stroke Risk Assessment and Future Stroke Primary Prevention Trials' held January 12-13, 2004 are summarized. The Workshop discussions focused on stroke risk assessment; the high-risk vs. population-based approaches to primary prevention; desirable characteristics of candidate treatments and potential novel treatments, such as the 'polypill'; subclinical disease as risk assessment tool and as surrogate outcome, and methodological issues in stroke primary prevention trials. The importance of assessing cognitive decline as an important consequence of covert and overt vascular injury of the brain was emphasized. The scientific or logistic barriers to stroke primary prevention trials are challenging, but are not insurmountable.

AB - Most (∼70%) of strokes are first-ever strokes, and hence to substantially reduce the neurological burden, primary prevention is crucial. Here, highlights of the National Institute of Neurological Disorders and Stroke workshop 'Stroke Risk Assessment and Future Stroke Primary Prevention Trials' held January 12-13, 2004 are summarized. The Workshop discussions focused on stroke risk assessment; the high-risk vs. population-based approaches to primary prevention; desirable characteristics of candidate treatments and potential novel treatments, such as the 'polypill'; subclinical disease as risk assessment tool and as surrogate outcome, and methodological issues in stroke primary prevention trials. The importance of assessing cognitive decline as an important consequence of covert and overt vascular injury of the brain was emphasized. The scientific or logistic barriers to stroke primary prevention trials are challenging, but are not insurmountable.

KW - Clinical trial

KW - Primary prevention

KW - Risk factors

KW - Stroke prevention

UR - http://www.scopus.com/inward/record.url?scp=22544468076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22544468076&partnerID=8YFLogxK

U2 - 10.1159/000086342

DO - 10.1159/000086342

M3 - Article

VL - 25

SP - 91

EP - 104

JO - Neuroepidemiology

JF - Neuroepidemiology

SN - 0251-5350

IS - 2

ER -